What ProBio Inc. does

ProBio Inc. is the Contract Development and Manufacturing Organization (CDMO) division of GenScript Biotech Corporation (HKEX: 1548), operating as a privately held subsidiary headquartered in Pennington, New Jersey with 101-250 employees. The company provides end-to-end biologics and cell & gene therapy manufacturing services spanning antibody discovery through commercial drug product, serving biotech and pharmaceutical clients globally across the US, China, Japan, South Korea, and Europe.

The core technology portfolio rests on proprietary CHO host cell line systems (CHOK1-GenS and CHOK1-ADCC+) licensed from ECACC and developed internally, supplemented by the ProBox process development toolbox (encoding ~200 documented technical challenges from ~100 CMC projects), the UproCHO media system delivering average 49% titer improvement, proprietary E. coli PowerS strains for plasmid manufacturing, and Beacon-based single B cell antibody discovery. Manufacturing infrastructure includes a 2,800L Nanjing pilot campus (104 batches/year), a 17,250L Zhenjiang commercial campus (126 batches/year), and a newly opened 128,000 sq. ft. Hopewell, New Jersey facility for plasmid and viral vector production launched July 2025. Service coverage extends from therapeutic antibody and recombinant protein CDMO through plasmid DNA, lentiviral vector, AAV vector, mRNA, and emerging modalities including ADCs, antibody-oligonucleotide conjugates, and in vivo CAR-T.

The business model operates on managed-services CDMO contracts with project-based milestone pricing and multi-year engagements, complemented by one-time cell line licensing fees and fee-for-service discovery work. Go-to-market is enterprise field sales with regional commercial teams across five markets, augmented by channel partnerships (GCP ClinPlus, MicroMedMark), event-driven demand generation at conferences such as the GenScript Biotech Global Forum, and referral co-development arrangements with over 30 biotech partners. The company has supported 130+ IND approvals across FDA, EMA, NMPA, and MFDS jurisdictions since 2017, with operational qualifications including EU QP audit passage, NMPA drug manufacturing license, and the first Korean MFDS GMP certification for a lentiviral vector facility.

Name

ProBio Inc.

Legal name

ProBio Inc.

Website

https://probiocdmo.com

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

101–250 employees

Short description

ProBio Inc. is a global biologics and cell & gene therapy CDMO, subsidiary of GenScript Biotech (HKEX:1548), providing end-to-end antibody discovery, cell line development, and GMP manufacturing services for biotech and pharmaceutical clients across the US, China, Japan, Korea, and Europe.

Ownership category

akta.pro rank

Product category

Biologics Contract Manufacturing (CDMO)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Cell Therapy CDMO (HLAGABAD), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF)

Keywords

• Biologics CDMO services
• Cell line development
• Viral vector manufacturing
• Antibody discovery
• Gene therapy manufacturing

Headquarters

HQ city

Pennington

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Biologics CDMO Services: Contract development and manufacturing services for biologics including antibodies, bispecific antibodies, and recombinant proteins. Services span from discovery through commercial manufacturing including cell line development, IND-enabling CMC, process characterization/validation, clinical and commercial drug substance manufacturing, and fill-finish services. Revenue generated through project-based contracts, typically milestone-based with recurring manufacturing engagements.
2. Cell & Gene Therapy (CGT) CDMO Services: Comprehensive viral vector and plasmid manufacturing services for cell and gene therapy programs. Includes plasmid DNA (LentiHelper, AAssistV products), lentiviral vectors, AAV vectors, and mRNA manufacturing. Services support preclinical through commercial phases with GMP-compliant manufacturing.
3. Cell Line Licensing: Licensing of proprietary CHOK1 cell line systems (CHOK1-GenS, CHOK1-ADCC+) for commercial biomanufacturing. One-time lumpsum payment with royalty-free terms. Includes vector systems and technical documentation.
4. Discovery Services: Fee-for-service antibody discovery and lead optimization including hybridoma generation, single B cell screening, human Fab library screening, bispecific antibody discovery, ADC discovery, and TCR engineering services.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Core offering

ProBio Inc. is a global Contract Development and Manufacturing Organization (CDMO) that provides end-to-end biologics and cell & gene therapy manufacturing services. Its portfolio spans antibody discovery (hybridoma, single B cell, transgenic mice, phage display), stable cell line development, IND-enabling CMC, process characterization and validation, GMP clinical and commercial drug substance manufacturing, aseptic fill-finish, bioanalytical services, plasmid DNA, lentiviral vector, AAV vector, and mRNA manufacturing. Services are delivered to biotech and pharmaceutical clients through facilities in Nanjing, Zhenjiang, and Hopewell, New Jersey.

Product overview

ProBio is a global CDMO providing end-to-end biologics and cell & gene therapy (CGT) manufacturing services. The portfolio includes Biologics Discovery Services (antibody lead generation, optimization, and pharmacology), Biologics CDMO (cell line development via CHOK1-GenS/CHOK1-ADCC+ systems, ExpressCMC™ IND-enabling CMC, perfusion bioprocess development, ProBox™ process development tools, UproCHO™ media system, GMP clinical and commercial manufacturing, and aseptic fill-finish), and CGT CDMO (Plasmid CDMO with LentiHelper™/AAssistV™ plasmids, Lentiviral Vector CDMO, AAV Vector CDMO, and mRNA CDMO with RNA-tLNP encapsulation). Additional specialized services include One-stop AOC CMC Service for antibody-oligonucleotide conjugates, High-concentration Protein Formulation Platform, and Antibody & Protein CMC for CGT. The company supports clients from target discovery through commercial manufacturing with capabilities spanning antibodies, recombinant proteins, plasmid DNA, mRNA, viral vectors, and in vivo CAR-T therapies.

Differentiator

Problem solved

Functional benefit

Products and services

• ProBio CDMO Services End-to-end biologics and advanced therapy CDMO services from target discovery through commercial manufacturing, serving pharmaceutical and biotechnology clients globally with manufacturing campuses in China and the United States.
• Biologics Discovery Services Comprehensive antibody discovery services including hybridoma generation, single B cell screening, transgenic mice, human Fab naïve library, bispecific antibody discovery, ADC discovery, TCR engineering, in vivo CAR-T discovery, antibody humanization, affinity maturation, Fc engineering, developability assessment, and in vitro/in vivo pharmacology services.
• ProCLD Cell Line Development Stable cell line development service using proprietary CHOK1-GenS and CHOK1-ADCC+ host cell line systems, delivering top 6 clones in 10 weeks from DNA with average titer 6 g/L and up to 15 g/L. Used by biotech and pharma clients developing monoclonal antibodies, bispecifics, and recombinant proteins.
• CHOK1-ADCC+ Cell Line System ADCC-enhanced host cell line system that produces afucosylated monoclonal antibodies with enhanced antibody-dependent cellular cytotoxicity (ADCC) activity, with affinity to CD16a increased by 3-4 times and cytotoxicity increased by approximately 10%. Used for cancer therapeutic antibody development.
• CHOK1-GenS Host Cell Line Proprietary wild-type CHO-K1 host cell line development system with high productivity and excellent stability, achieving average mAb titer of 5.7 g/L and maximum up to 15 g/L. Licensed for commercial manufacturing under royalty-free terms via ECACC license agreement with proprietary pGenHT 1.0-UP vector.
• ExpressCMC IND-enabling CMC Fast-track IND-enabling CMC development service delivering 4 months from DNA to tox batch and 9 months from DNA to GMP drug product for monoclonal antibodies and symmetric bispecific antibodies, with process and analytical development supported by ProBox toolbox.
• ProBox Process Development Toolbox Integrated biologics process development solution built on approximately 100 CMC projects, classifying and integrating approximately 200 technical challenges and solutions in process and analytical development for multiple bispecific antibody types and proteins, updated in real-time.
• UproCHO Medium System Proprietary cell culture media system designed for the CHOK1-GenS cell line that optimizes productivity and product quality in fed-batch, intensified fed-batch, and perfusion cultures. Demonstrated titer improvement in over 90% of projects with an average improvement of 49% and maximum 117%. Manufactured in ISO 13485 certified facilities.
• Perfusion Bioprocess Development Continuous bioprocessing development service achieving 10-20x higher productivity and up to 88 g/L titer with 60-80% COGS reduction, delivering 10 months from DNA to tox batch and 13 months from DNA to drug product ready. Used for biologics manufacturing intensification.
• Process Characterization and Validation BLA readiness service achieving process characterization completion in 14 months with 40-60% cost reduction through process optimization. Includes multidimensional process optimization, CPP/CQA evaluation, upstream and downstream process characterization, and PPQ validation for late-stage biologics programs.
• 200-500L Drug Substance Manufacturing Phase I/II clinical GMP drug substance manufacturing service at the Nanjing pilot campus with 2,800L total bioreactor capacity and 104 batches annual manufacturing capacity. Supports preclinical non-GMP toxicology batch manufacturing and clinical phase 1/2 GMP drug substance manufacturing with FDA, EMA, and NMPA GMP compliance.
• 2000L Commercial Manufacturing Phase III clinical and commercial GMP drug substance manufacturing service at the Zhenjiang commercial campus with 17,250L total capacity and 126 batches annual manufacturing capacity. Equipped with single-use bioreactors from 50L to 2000L, stainless steel buffer preparation system, and 8,000L harvest tank supporting scale-out mode. Compliant with FDA, EMA, and NMPA GMP regulations.
• Aseptic Fill and Finish Automated aseptic filling services including liquid injection, lyophilized injection, prefilled syringe, and nasal spray formats. Pilot line in Nanjing (30,000 pcs/batch) and commercial filling line in Zhenjiang (192,000 pcs/batch) for clinical and commercial supply.
• Bioanalytical Services Comprehensive bioanalytical services with over 50 developed methods supporting over 200 NME programs. Includes biochemical assays, cell-based assays, and protein analytics using HTS, FACS, Biacore, and LC-MS platforms for biologics characterization and release.
• Plasmid CDMO Services End-to-end plasmid manufacturing services including LentiHelper and AAssistV off-the-shelf packaging plasmid products, GMPro GMP plasmid manufacturing with guaranteed ≥85% supercoiled DNA content delivered in 3 months, and linearized DNA manufacture for cell and gene therapy applications.
• Lentiviral Vector CDMO End-to-end lentiviral vector (LVV) CDMO services including cell line development, cell banking, LVV drug product one-stop solution, and GMP manufacturing supporting both adherent and suspension platforms for cell and gene therapy programs. Includes proprietary LVV BLA process characterization and validation services.
• AAV Vector CDMO AAV vector manufacturing services using proprietary PowerS-293 suspension cell line, including ProAAV, AAV one-stop solution, and GMP manufacturing from research through commercial phases. Supports AAV gene therapy development with CGMP compliance.
• mRNA CDMO Services mRNA manufacturing services from plasmid through LNP encapsulation, including mRNA IND-enabling CMC, GMP mRNA manufacturing, and RNA-tLNP one-stop solution for vaccines and therapeutics applications.
• One-stop AOC CMC Service Antibody-Oligonucleotide Conjugate (AOC) development service combining antibody and oligonucleotide CMC expertise with platform processes and dedicated analytical methods. Delivers 10.5 months from DNA to GMP drug product, or 8.5 months for mAb and symmetric bispecific antibody formats. Supports both random and site-specific conjugation.
• High-concentration Protein Formulation Platform Specialized platform for high-concentration protein formulations achieving concentrations up to 150 mg/mL with expertise across mAb, bsAb, TsAb, and Fc fusion modalities for subcutaneous (SC), intravenous (IV), and intravitreal (IVT) routes of administration.
• Antibody and Protein CMC for CGT Flexible antibody and protein CMC solutions for cell and gene therapy applications delivering 3.5 months from DNA to IIT material and 5 months from DNA to GMP batch, supporting cell therapy and gene therapy programs.
• GMPro Cell Banking GMP-compliant cell banking services for MCB (Master Cell Bank) and WCB (Working Cell Bank) generation and storage, featuring cGMP-compliant service, independent liquid nitrogen tanks, and 24-hour security monitoring for biologics manufacturing programs.
• Viral Vector Packaging Test New early-stage development service to help biopharma companies make go/no-go decisions and de-risk progression from discovery to CMC in cell and gene therapy programs. Supports lentiviral vector and AAV modalities with 3-5 week turnaround times using the same cell lines and plasmids as later-stage manufacturing.

Quantifiable outcome

• 4 months from DNA to tox batch for monoclonal antibodies
• +7 more outcomes

Named customers12 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

38 partnerships are on record, tiered core, flagship and minor.

• GCP ClinPluscoreStrategic or Co-development Partner · 3 June 2026Strategic collaboration to accelerate Investigator-Initiated Trials (IITs) in China. Combines ProBio's biologics and cell and gene therapy CDMO expertise with GCP ClinPlus's clinical trial execution capabilities and hospital network. Provides integrated, end-to-end clinical and development solutions for global biopharma companies entering China's clinical research ecosystem.
• Curocell Inc.coreStrategic or Co-development Partner · 11 May 2026Strategic CDMO partnership achieving BLA regulatory approval for Anbal-cel (CRC01), Korea's first domestically developed CAR-T therapy. ProBio served as strategic CDMO partner, completing process characterization within four months and securing MFDS GMP certification for lentiviral vector manufacturing - the first-ever for a lentiviral vector facility in Korea. Program now entering commercial manufacturing phase.
• UCI TherapeuticscoreStrategic or Co-development Partner · 1 September 2024Strategic MOU to develop NK cell gene introduction technologies. Comprehensive collaboration in gene delivery technologies including viral and non-viral approaches for advanced cell therapy development.
• GeneCraftcoreStrategic or Co-development PartnerMOU partnership for development and production of AAV gene therapies. Successfully supported MFDS clearance for RX001 - the world's first AAV-based lung cancer therapy.
• GenScript Biotech CorporationflagshipStrategic or Co-development PartnerProBio is a subsidiary of GenScript Biotech Corporation (HKEX: 1548). GenScript is a global leader in synthetic biology founded in 2002, providing the parent company's expertise and resources to support ProBio's CDMO operations.
• ABL Bio Inc.coreStrategic or Co-development PartnerBispecific antibody strategic partnership. ProBio supported IND clearance from MFDS for ABL103 program.
• SelecxinecoreStrategic or Co-development PartnerStrategic cooperation for innovative antibody drug program development. Supported FDA clearance of IND application.
• REMD BiotherapeuticscoreOEM/ Whitelabel/ Licensing PartnerLicensed global rights to develop and commercialize SMAB bispecific antibody molecule. Jointly developed bispecific antibody received IND clearance from NMPA.
• InnoBation BiocoreStrategic or Co-development PartnerCDMO contract for next-generation CD47 antibody. Successfully supported MFDS clearance of IBC101 program.
• RVAC MedicinescoreStrategic or Co-development PartnerStrategic partnership for GMP plasmid DNA manufacturing for mRNA COVID-19 vaccine candidate.
• National Cancer Center, JapancoreStrategic or Co-development PartnerResearch collaboration agreement for plasmid and lentiviral vector CMC development.
• Experimental Drug Development Centre (EDDC), SingaporecoreStrategic or Co-development PartnerCollaboration for anti-fibrosis therapeutic antibody programme development.
• Comprehensive Cell Solutions, New York Blood Center EnterprisescoreStrategic or Co-development PartnerPioneering partnership to expedite cell and gene therapy development and manufacturing.
• ACT TherapeuticscoreStrategic or Co-development PartnerMOU for development of new CAR-T cell therapies.
• AthenexcoreStrategic or Co-development PartnerPartnership for development of advanced cell and gene therapies.
• ProteoNic BVcoreTechnology or IntegrationStrategic cooperation based on high expressing vector system for improved biologics manufacturing.
• Ligand PharmaceuticalscoreTechnology or IntegrationGlobal OmniAb licensing agreement for transgenic antibody discovery platform access.
• MicroMedMarkminorChannel Partner/ Reseller/ DistributorCDMO partner relationship for biologics services.
• WALVAXcoreStrategic or Co-development PartnerCDMO partnership for novel drug development.
• GenScript-Thermo Fisher ScientificcoreStrategic or Co-development PartnerStrategic partnership on life sciences and biopharma services.
• ECACC (European Collection of Authenticated Cell Cultures)coreTechnology or IntegrationLicensing agreement for CHO-K1 commercial license for biomanufacturing. ProBio is one of the earliest companies to obtain CHO-K1 commercial license from ECACC.
• EyeGenecoreStrategic or Co-development PartnerSupported clinical trial approval for mRNA COVID-19 vaccine in South Korea.
• TG ImmunoPharmacoreStrategic or Co-development PartnerCollaboration on innovative antibody drug project. Supported FDA clearance of clinical trial for TGI-5 monoclonal antibody.
• SunRock BiopharmacoreStrategic or Co-development PartnerCollaboration agreement for novel monoclonal antibody program development.
• NeoletixcoreStrategic or Co-development PartnerSuccessful completion of 200-Liter GMP production runs of recombinant Coagulation FVIII. Signed LOI for clinical and commercial production of recombinant human coagulation factor VIII.
• AffyXell TherapeuticscoreStrategic or Co-development PartnerCDMO supply agreement and strategic partnership - joint venture between Daewong and Avacta.
• DAAN Bio TherapeuticscoreStrategic or Co-development PartnerStrategic cooperation MOU for discovery and development of novel drugs.
• XLifeSccoreStrategic or Co-development PartnerSupported FDA allowance of IND application for TCR-T program.
• EutilexcoreStrategic or Co-development PartnerSupported IND clearance from MFDS for innovative antibody drug program.
• Beroni GroupcoreStrategic or Co-development PartnerAgreement to develop nanobody-based medical solution for COVID-19.
• Cell Resources Corporation (Alfresa Holdings)coreStrategic or Co-development PartnerCollaboration agreement for cell therapy development.
• Hibiocy Co. Ltd (Rojukiss International)coreStrategic or Co-development PartnerStrategic collaboration for development and manufacturing of COVITRAP and future novel products.
• mAbsolvecoreTechnology or IntegrationLicensed novel Fc silencing technology for antibody development.
• Dx&VxcoreStrategic or Co-development PartnerStrategic partnership for novel drug development.
• Bio ImmunitascoreStrategic or Co-development PartnerJoint collaboration leading to development and fast track manufacturing of novel therapeutic platform.
• NuclixBiocoreStrategic or Co-development PartnerMOU for strategic collaboration in gene therapy development.
• Initium TherapeuticscoreStrategic or Co-development PartnerStrategic collaboration leveraging clinical trial execution capabilities and hospital network for IIT programs.
• ChimagencoreStrategic or Co-development PartnerAccelerating global market expansion for innovative antibody therapy.

Scale indicators15 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• WuXi Biologics: The leading biologics CDMO globally and the most direct China-anchored peer. Both offer end-to-end discovery, cell line development, and GMP biologics manufacturing with the CHOK1 platform — competing for the same Asian and global biotech customer base.
• Samsung Biologics: Large-scale Korean biologics CDMO with multiple mega-plants. Competes directly with ProBio for both clinical and commercial mammalian biologics manufacturing, especially in the Korean and broader APAC market.
• AGC Biologics: Mid-sized global biologics and CGT CDMO with facilities in the US, Europe, and Asia. Competes head-to-head for mammalian biologics, viral vector, and gene therapy programs across ProBio's key modalities.
• Rentschler Biopharma: Germany-based pure-play biologics CDMO focused on mammalian cell culture and cell line development. Closely comparable as a mid-sized, quality-focused alternative for clients evaluating ProBio for clinical and commercial mAb/bispecific manufacturing.
• Forge Biologics: US-based CDMO purpose-built for AAV and gene therapy manufacturing. Direct competitor in the US CGT CDMO market and a key alternative for clients concerned about China-anchored viral vector supply.
• Bora Pharmaceuticals: Taiwan-headquartered CDMO expanding into biologics and complex formulations. Competes with ProBio in Asia-Pacific large-molecule fill-finish and clinical/commercial biologics manufacturing.

Broad incumbents

• Lonza Group: Global CDMO leader with the broadest biologics, cell therapy, and viral vector service portfolio. Overlaps with ProBio across nearly every modality at larger scale and serves as the primary competitor for Big Pharma outsourcing contracts.
• Catalent: Major diversified CDMO with biologics fill-finish, cell therapy, and plasmid/viral vector services. Overlaps with ProBio on aseptic fill-finish, cell line development, and CGT, though Catalent is more US-anchored and recently acquired by Novo Holdings.
• Thermo Fisher Scientific (Patheon CDMO): Operates one of the largest global CDMO networks through Patheon and viral vector services through Brammer Bio. Overlaps with ProBio in cell line development, biologics GMP manufacturing, and viral vector production across a far broader global footprint.

Regional players

• Celltrion: Korean biopharmaceutical company that operates CDMO-adjacent contract manufacturing services. Competes with ProBio in Korean and Asian commercial biologics manufacturing, especially for monoclonal antibody supply.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ProBioCDMO

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ProBio Inc.